Patents Examined by Aradhana Sasan
  • Integrin binding peptides and uses thereof
    Patent number: 11634470
    Abstract: The disclosure relates to integrin binding peptides, pharmaceutical compositions comprising the peptides and to uses thereof as therapeutic, diagnostic, imaging and targeting agents.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: April 25, 2023
    Assignees: Universiteit Twente
    Inventor: Jai Prakash
  • Peptides and compositions for use in cosmetics and medicine
    Patent number: 11634458
    Abstract: The present invention relates to a family of peptides which are able to interfere in the formation of complex Munc18-Syntaxin-1 and, hence, are useful in the prevention and/or treatment of neuronal exocytosis and/or muscle contractility disorders; and to prevent, reduce and/or eliminate skin aging and/or expression signs.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: April 25, 2023
    Assignee: LIPOTRUE, S.L.
    Inventors: Ariadna Grau-Campistany, Silvia Pastor, Patricia Carulla, Juan Carlos Escudero, Julia A. Boras, Isabel Devesa Giner, Gregorio Fernandez Ballester
  • Modulators of notch signaling and methods of use thereof
    Patent number: 11613567
    Abstract: Described herein are Notch-modulating peptides (including monomers and multimers) capable of increasing or decreasing an immune response in a subject, compositions comprising the peptides, and methods of use thereof.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: March 28, 2023
    Assignee: Ohio State Innovation Foundation
    Inventors: Thomas J. Magliery, Mikhail M. Dikov, David Carbone, Nicholas Long, Brandon Sullivan, Elena Tchekneva
  • Acylated GLP-1 derivative
    Patent number: 11612640
    Abstract: Provided are a GLP-1(7-37) polypeptide analogue, a fatty acid-modified derivative of the analogue, and a medicament comprising the derivative. Further, also provided are a preparation method of the derivative, and use of the same in the preparation of a medicament.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: March 28, 2023
    Assignee: SCIWIND BIOSCIENCES CO., LTD.
    Inventors: Zheng Xu, Feng Li, Rui Song, Wanjun Guo, Hai Pan, Jing Feng
  • Compositions for the treatment of articular disorders
    Patent number: 11612628
    Abstract: The present invention relates to new compositions suitable for use in the treatment of articular disorders (or conditions), processes for preparing said compositions and use of said compositions in therapeutic treatments of articular disorders.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: March 28, 2023
    Assignee: Aboca S.p.A. Società Agricola
    Inventors: Valentino Mercati, Carla Ghelardini, Lorenzo Di Cesare Mannelli
  • Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions
    Patent number: 11612661
    Abstract: Provided herein are alpha-conotoxin peptide analogs, including alpha-conotoxin peptide analogs that are covalently attached to polyethylene glycol (PEG), and pharmaceutical compositions of such alpha-conotoxin peptide analogs. Also provided herein are methods of treating or preventing a condition conducive to treatment or prevention by inhibition of an ?9-containing nicotinic acetylcholine receptor (nAChR) (e.g., the ?9?10 subtype of the nAChR) in a subject.
    Type: Grant
    Filed: January 3, 2020
    Date of Patent: March 28, 2023
    Assignee: Kineta Chronic Pain, LLC
    Inventors: Jose Mercado, Eric J. Tarcha, Jeffrey J. Posakony, Shawn Iadonato
  • Therapeutic molecules
    Patent number: 11608371
    Abstract: The present invention relates to effective pain therapies in companion animals. In particular, an isolated companion animal p75NTR protein or a fusion protein containing the same or portions thereof are contemplated. Nucleic acids encoding the proteins are also encompassed in the invention as well as methods of using the same.
    Type: Grant
    Filed: October 21, 2021
    Date of Patent: March 21, 2023
    Assignee: PETMEDIX LTD
    Inventors: Meng Amy Li, Marco Bardelli
  • Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
    Patent number: 11602512
    Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.
    Type: Grant
    Filed: October 8, 2021
    Date of Patent: March 14, 2023
    Assignee: Flamel Ireland Limited
    Inventors: Jordan Dubow, Hervé Guillard, Claire Mégret, Jean-François Dubuisson
  • Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
    Patent number: 11602513
    Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.
    Type: Grant
    Filed: October 8, 2021
    Date of Patent: March 14, 2023
    Assignee: Flamel Ireland Limited
    Inventors: Jordan Dubow, Hervé Guillard, Claire Mégret, Jean-François Dubuisson
  • Emollient topical disinfectants
    Patent number: 11596648
    Abstract: This invention relates generally to an emollient topical composition of matter that contains molecular iodine with a reduced effective vapor pressure. In specific embodiments, the composition reduces the loss of molecular iodine to the atmosphere under storage conditions after application to mammalian tissue.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: March 7, 2023
    Assignee: I2PURE CORP.
    Inventors: Jack Kessler, David C. Litzinger, Christopher Rhodes, Andrew M. Cerro
  • Methods of using and compositions containing dulaglutide
    Patent number: 11576950
    Abstract: The present invention relates to methods of using new doses of dulaglutide and compositions containing such higher doses of dulaglutide.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: February 14, 2023
    Assignee: Eli Lilly and Company
    Inventors: David Andrew Cox, Zvonko Milicevic, Lai San Tham, David Bradley Woodward
  • Tablets having discontinuous coated regions
    Patent number: 11576867
    Abstract: A dosage form comprising a tablet core and one or more discontinuous coated regions in various configurations on the surface of the dosage form is disclosed. A method for making the dosage form is also disclosed.
    Type: Grant
    Filed: January 28, 2020
    Date of Patent: February 14, 2023
    Assignee: Johnson & Johnson Consumer Inc.
    Inventors: Harry Sowden, Gerard McNally, Der-Yang Lee
  • Injectable solution at pH 7 comprising at least one basal insulin for which the pI is from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
    Patent number: 11576952
    Abstract: A composition in the form of an injectable aqueous solution, whose pH consists from 6.0 to 8.0, including at least: a basal insulin whose isoelectric point includes from 5.8 to 8.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: February 14, 2023
    Assignee: ADOCIA
    Inventor: Richard Charvet
  • Pharmaceutical compositions comprising Ibrutinib
    Patent number: 11576917
    Abstract: The present invention relates to pharmaceutical compositions comprising Ibrutinib. More particularly, the present invention relates to a tablet composition comprising Ibrutinib and one or more pharmaceutically acceptable excipients and process for preparing such compositions.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: February 14, 2023
    Assignee: NATCO PHARMA LIMITED
    Inventors: Vattikuti Satyanarayana, Bhavanasi Krishna Murthy, Yalamanchalli Naveen Krishna, Bhat Pavan, Nannapaneni Venkaiah Chowdary
  • Skin care composition and method of using the same
    Patent number: 11571378
    Abstract: A skin care composition that includes a combination of palmitoyl dipeptide-7, acetyl tetrapeptide-11, other optional skin ingredients, and a dermatologic ally acceptable carrier. The combination of peptides synergistically improves cellular ATP level and/or upregulates the expression of peroxisome proliferator activated receptor alpha and/or methylsterol monooxygenase 1 to help provide improved skin health and appearance.
    Type: Grant
    Filed: January 22, 2021
    Date of Patent: February 7, 2023
    Assignee: The Procter & Gamble Company
    Inventors: Leo Timothy Laughlin, II, Michael Joseph Flagler, Lisa Ann Mullins, Makio Tamura
  • Composition including melittin for removing M2-type tumor-associated macrophage
    Patent number: 11571460
    Abstract: The present invention relates to a composition including melittin as an active ingredient for removing an M2-type tumor-associated macrophage (TAM), and more specifically, the present invention relates to a composition exhibiting an effect of selectively suppressing only M2-type tumor-associated macrophages among tumor-associated macrophages. The composition according to the present invention only suppresses M2-type tumor-associated macrophages without affecting M1-type tumor-associated macrophages or cancer cells, thus exhibiting anti-cancer and metastasis suppressing effects by blocking angiogenesis through control of the microenvironment of cancer cells, while reducing the side-effects of existing anti-cancer effects.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: February 7, 2023
    Assignee: LENUS LAB
    Inventors: Hyunsu Bae, Chan-Ju Lee
  • Protein pores
    Patent number: 11572387
    Abstract: The present invention relates to novel protein pores and their uses in analyte detection and characterisation. The invention particularly relates to an isolated pore complex formed by a CsgG-like pore and a modified CsgF peptide, or a homologue or mutant thereof, thereby incorporating an additional channel constriction or reader head in the nanopore. The invention further relates to a transmembrane pore complex and methods for production of the pore complex and for use in molecular sensing and nucleic acid sequencing applications.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: February 7, 2023
    Assignees: VIB VZW, Vrije Universiteit Brussel, Oxford Nanopore Technologies PLC
    Inventors: Han Remaut, Sander Egbert Van Der Verren, Nani Van Gerven, Lakmal Nishantha Jayasinghe, Elizabeth Jayne Wallace, Pratik Raj Singh, Richard George Hambley, Michael Robert Jordan, John Joseph Kilgour
  • Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors
    Patent number: 11560408
    Abstract: Disclosed is a new class of conjugated virus-like particles (VLPs). These conjugated VLPs bind a wide variety of tumors and comprise epitopes recognized by a prior T cell immune response already existing in a host. These epitopes are derived from pathogens or previous vaccinations (such as early childhood vaccines). This provokes the body's pre-existing cytotoxic immunity obtained through previous infection or previous childhood vaccination to be redirected to the tumor cells for the elimination of cancer, and form long-term anti-tumor immunity. The described conjugated VLPs are useful for tailoring a broad range of tumors towards a response from existing immunity circumventing the need to identify tumor antigens or generate tumor-specific immune responses.
    Type: Grant
    Filed: December 26, 2019
    Date of Patent: January 24, 2023
    Assignee: VERIMMUNE INC.
    Inventors: Joshua Weiyuan Wang, Nattha Ingavat, Ken Matsui
  • Tissue-homing peptide conjugates and methods of use thereof
    Patent number: 11559580
    Abstract: Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or bind to the cartilage or kidney of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of an active agent to a target region, tissue, structure or cell in the cartilage. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures, or cells targeted by the peptide.
    Type: Grant
    Filed: August 23, 2021
    Date of Patent: January 24, 2023
    Assignee: BLAZE BIOSCIENCE, INC.
    Inventors: Stacey J. Hansen, Claudia Jochheim, Dennis M. Miller, Natalie Winblade Nairn, Julia E. Novak, Mark R. Stroud, Valorie R. Wiss, Kelly Byrnes-Blake, Scott Presnell
  • Peptides derived from fibronectin with improved bioactivity and reduced susceptibility to neutrophil elastase degradation
    Patent number: 11548935
    Abstract: Polypeptides derived from fibronectin are presented that are neutrophil elastase-resistant and can bind to growth factors and/or enhance growth factor activity. These polypeptides are useful for enhancing wound healing in a patient.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: January 10, 2023
    Assignee: NeoMatrix Therapeutics Inc.
    Inventors: Richard August Clark, Fubao Lin